Schizophrenia  >>  PF-02545920  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PF-02545920 / Pfizer
NCT00570063: Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo

Terminated
2
35
US
PF-02545920, Placebo
Pfizer
Schizophrenia
02/08
02/08
NCT01175135 / 2010-020764-38: An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

Completed
2
259
US, Europe, RoW
PF-02545920, Placebo, Risperidone, Risperdal
Pfizer
Schizophrenia
08/11
08/11
NCT01939548: An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

Terminated
2
240
US
PF-02545920, 5 mg BID, Placebo, 15 mg BID
Pfizer
Schizophrenia
10/14
10/14

Download Options